Sanofi ADS (SNY) DIvidends Date & History

Key Takeaways

• Sanofi offers a forward dividend yield of approximately 5%, competitive among large pharmaceutical peers.
• The company has increased its dividend for 30 consecutive years, with a proposal for the 31st in 2026.
• Annual dividend payment of about $2.42 per ADR share, paid once per year.
• Payout ratio around 96%, but supported by strong free cash flow of over $7 billion TTM.
• Upcoming ex-dividend date May 4, 2026, with payment June 3, 2026.
• Sustainable profile backed by robust cash flows in the pharmaceutical sector.

Dividend Overview

Sanofi (SNY), a global healthcare company focused on pharmaceuticals and vaccines, maintains a progressive dividend policy. The Board proposes distributing a portion of annual profits as dividends, subject to shareholder approval. The forward annual dividend is approximately $2.42 per American Depositary Receipt (ADR) share, yielding about 5% based on recent stock prices. Dividends are paid annually, typically in May or June following the ex-dividend date in early May. Sanofi is regarded as a dividend growth stock, with a history of reliable increases rather than pursuing the highest yields. This approach appeals to investors seeking steady income with moderate growth in the stable pharma sector.

Dividend History and Growth

Sanofi has demonstrated exceptional dividend consistency, with the Board proposing a €4.12 per ordinary share dividend for fiscal 2025 results in January 2026—potentially the 31st consecutive annual increase. Recent ADR payments include $2.212 in June 2025 (ex-May 9, 2025) and $2.037 in June 2024, reflecting steady growth of around 4-8% annually over the past five years. This long-term strategy prioritizes shareholder returns amid R&D investments and business development. No cuts have occurred in decades, underscoring commitment to dividend progression.

Dividend Sustainability and Payout Ratio

Sanofi's payout ratio stands at approximately 96% of trailing twelve-month earnings per share (EPS) of $2.38, which is elevated but typical for mature pharma firms balancing growth investments. However, sustainability is bolstered by robust cash generation: trailing twelve-month free cash flow (FCF) reached $7.212 billion, with annual operating cash flow at $10.75 billion. This comfortably covers total dividend obligations. Debt levels are manageable, and the company's diversified portfolio in immunology, neurology, and rare diseases supports ongoing coverage. Free cash flow per share further affirms the dividend's security despite the high payout.

Dividend Compared to Industry Peers

Sanofi's forward yield of about 5% positions it favorably against large-cap pharmaceutical peers. JNJ (Johnson & Johnson) offers around 2.3%, emphasizing stability as a Dividend King. ABBV (AbbVie) yields roughly 3.3%, driven by immunology blockbusters. MRK (Merck) is lower at about 2.5%, while PFE (Pfizer) provides a higher 6-7% amid post-COVID adjustments. Sanofi's yield and growth streak make it an attractive middle-ground option in the sector, blending income and appreciation potential.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It efficiently identifies dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more effectively than manual screening. Explore the AI Screener to enhance your research process today.

Is This Stock Attractive for Dividend Investors?

Sanofi (SNY) suits dividend growth investors who prioritize long-term consistency over ultra-high yields. Its 31-year streak of increases appeals to those building portfolios for compounding income, particularly in defensive healthcare. Income-focused investors may appreciate the 5% forward yield, which exceeds many blue-chip pharma peers and provides reliable annual payouts amid market volatility. Conservative, long-term holders benefit from Sanofi's strong FCF coverage and diversified revenue from vaccines and specialty drugs, offering resilience against patent cliffs or R&D risks. However, the high payout ratio warrants monitoring earnings growth. Balanced investors valuing stability over aggressive growth may find SNY a solid holding, though sector headwinds like pricing pressures apply. Overall, it fits moderately conservative dividend strategies seeking pharma exposure.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations